Home > Publications Database > Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial. > print

001     279900
005     20250824001659.0
024 7 _ |a 10.1002/alz.70347
|2 doi
024 7 _ |a pmid:40660741
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
024 7 _ |a altmetric:179480622
|2 altmetric
037 _ _ |a DZNE-2025-00860
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a McCullough, Austin
|b 0
245 _ _ |a Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755680933_25772
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Monoclonal anti-amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD).In the DIAN-TU-001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [11C]-Pittsburgh compound-B (PiB) positron emission tomography (PET), [18F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI).Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. Drug effects were associated with baseline PiB-PET uptake, and the largest effects occurred in medial regions.Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB-PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design.Gantenerumab unevenly decreased Aβ burden as measured by PiB-PET across brain regions. The strongest decrease in PiB-PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG-PET metabolism or MRI volumetrics after 4 years.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a DIAN‐TU
|2 Other
650 _ 7 |a FDG‐PET
|2 Other
650 _ 7 |a MRI measures
|2 Other
650 _ 7 |a PET
|2 Other
650 _ 7 |a amyloid targeted monoclonal antibody
|2 Other
650 _ 7 |a autosomal dominant Alzheimer's disease (ADAD)
|2 Other
650 _ 7 |a dominantly inherited Alzheimer's disease (DIAD)
|2 Other
650 _ 7 |a gantenerumab
|2 Other
650 _ 7 |a imaging outcomes
|2 Other
650 _ 7 |a regional PiB‐PET uptake
|2 Other
650 _ 7 |a regional variability
|2 Other
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 7 |a gantenerumab
|0 4DF060P933
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Thiazoles
|2 NLM Chemicals
650 _ 7 |a Fluorodeoxyglucose F18
|0 0Z5B2CJX4D
|2 NLM Chemicals
650 _ 7 |a Aniline Compounds
|2 NLM Chemicals
650 _ 7 |a 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: drug therapy
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: drug effects
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: therapeutic use
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: pharmacology
|2 MeSH
650 _ 2 |a Neuroimaging
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Biomarkers: metabolism
|2 MeSH
650 _ 2 |a Thiazoles
|2 MeSH
650 _ 2 |a Fluorodeoxyglucose F18
|2 MeSH
650 _ 2 |a Aniline Compounds
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DIAN-20090101
|5 EXP:(DE-2719)DIAN-20090101
|e Longitudinal Study on Dominantly Inherited Alzheimer's Disease
|x 0
700 1 _ |a Chen, Charles D
|b 1
700 1 _ |a Gordon, Brian A
|b 2
700 1 _ |a Joseph-Mathurin, Nelly
|b 3
700 1 _ |a Jack, Clifford R
|b 4
700 1 _ |a Koeppe, Robert
|b 5
700 1 _ |a Hornbeck, Russ
|b 6
700 1 _ |a Koudelis, Deborah
|b 7
700 1 _ |a McKay, Nicole S
|b 8
700 1 _ |a Hobbs, Diana A
|b 9
700 1 _ |a Flores, Shaney
|b 10
700 1 _ |a Keefe, Sarah J
|b 11
700 1 _ |a Aggarwal, Neelum T
|b 12
700 1 _ |a Allegri, Ricardo F
|b 13
700 1 _ |a Berman, Sarah B
|b 14
700 1 _ |a Bird, Thomas
|b 15
700 1 _ |a Black, Sandra E
|b 16
700 1 _ |a Brooks, William S
|b 17
700 1 _ |a Chhatwal, Jasmeer P
|b 18
700 1 _ |a Day, Gregory S
|b 19
700 1 _ |a Farlow, Martin R
|b 20
700 1 _ |a Fox, Nick C
|b 21
700 1 _ |a Gauthier, Serge
|b 22
700 1 _ |a Honig, Lawrence S
|b 23
700 1 _ |a Hsiung, Ging-Yuek
|b 24
700 1 _ |a Jucker, Mathias
|0 P:(DE-2719)2000010
|b 25
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 26
|u dzne
700 1 _ |a Masellis, Mario
|b 27
700 1 _ |a Masters, Colin
|b 28
700 1 _ |a Mendez, Patricio Chrem
|b 29
700 1 _ |a Ringman, John M
|b 30
700 1 _ |a Snider, B Joy
|b 31
700 1 _ |a Salloway, Stephen
|b 32
700 1 _ |a Schofield, Peter R
|b 33
700 1 _ |a Shimada, Hiroyuki
|b 34
700 1 _ |a Suzuki, Kazushi
|b 35
700 1 _ |a van Dyck, Christopher H
|b 36
700 1 _ |a Klein, Gregory
|b 37
700 1 _ |a Clifford, David B
|b 38
700 1 _ |a Cruchaga, Carlos
|b 39
700 1 _ |a Hassenstab, Jason
|b 40
700 1 _ |a Li, Yan
|b 41
700 1 _ |a McDade, Eric
|b 42
700 1 _ |a Mills, Susan
|b 43
700 1 _ |a Morris, John C
|b 44
700 1 _ |a Perrin, Richard J
|b 45
700 1 _ |a Supnet-Bell, Charlene
|b 46
700 1 _ |a Wang, Guoqiao
|b 47
700 1 _ |a Xiong, Chengjie
|b 48
700 1 _ |a Bateman, Randall J
|b 49
700 1 _ |a Benzinger, Tammie L S
|b 50
700 1 _ |a Team, DIAN-TU Study
|b 51
|e Collaboration Author
773 _ _ |a 10.1002/alz.70347
|g Vol. 21, no. 7, p. e70347
|0 PERI:(DE-600)2201940-6
|n 7
|p e70347
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/279900/files/DZNE-2025-00860%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/279900/files/DZNE-2025-00860.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/279900/files/DZNE-2025-00860.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:279900
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2000010
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2811659
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurological Diseases
|x 0
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210001
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21